On April 14, 2026, Hao Deming, Founding President of the China Association of Non‑Public Medical Institutions and Chairperson of its International Cooperation and Exchange Committee, along with his delegation, paid a visit to Nanjing Zijin Hospital to conduct a special research mission and hold a symposium on the selection of pilot hospitals for the Lingshui International Innovation Pilot Program for Pharmaceuticals and Medical Devices, the establishment of the Lingshui International Innovation Consortium for Non‑Public Medical Services (hereinafter referred to as the “Non‑Public Medical Consortium”), and the integration of commercial health insurance. Ge Jiangping, President of Nanjing Zijin Hospital, Vice Presidents Gao Zhiqiang and Wang Yifang, together with heads of relevant departments, attended the meeting, which was chaired by President Ge Jiangping.

　　At the outset of the meeting, Dean Ge Jiangping, on behalf of the hospital, extended a warm welcome to President Hao Deming and his delegation, and expressed sincere gratitude to the China Association for Non-public Medical Institutions for its longstanding efforts in establishing a high‑level platform for industry‑wide exchange and cooperation. Dean Ge provided a brief overview of Nanjing Zijin Hospital, highlighting its clinical strengths, and focused on reporting the preparatory work undertaken to introduce cutting‑edge international pharmaceuticals and medical devices, as well as the hospital’s collaborative aspirations and progress in aligning with commercial insurance reimbursement mechanisms. Dean Ge emphasized that the hospital places great importance on the introduction and application of world‑class medical technologies, and looks forward to accelerating the application process and preparatory work for pilot‑hospital designation under the association’s guidance, so that more innovative advances can benefit patients.

　　In his address, President Hao Deming systematically outlined the development trajectory, policy advantages, and innovative achievements of Hainan Boao Lecheng International Medical Tourism Pilot Zone, and provided an in-depth analysis of the national policies supporting the introduction and use of internationally innovative, specially authorized medical devices and pharmaceuticals, as well as their core clinical value. President Hao emphasized that non‑public medical consortia represent an extension and expansion of public‑hospital‑based medical consortiums into the non‑public hospital sector, offering member hospitals a historic opportunity to connect with the nation’s cutting‑edge medical innovation platforms.

　　Chairman Hao Deming emphasized that the development of non‑public medical consortia will strictly adhere to four core principles: upholding the bottom line of medical quality and safety; ensuring that real‑world data are authentic and traceable; implementing unified management standards; and strictly prohibiting the unauthorized use or leakage of data, pharmaceuticals, and medical devices. At the same time, the “Four Determinations” work plan will be fully implemented—designating pilot hospitals, specifying licensed products, establishing standardized operating procedures, and defining evaluation criteria—to ensure that the medical consortium gets off to a high‑standard start, operates with high quality, and complies throughout the entire process.

　　During the panel discussion, Gao Zhiqiang, Executive Vice President of Nanjing Zijin Hospital, along with heads of relevant clinical departments, sought on-site advice from association experts on key issues such as the approval procedures for introducing innovative international medical devices and pharmaceuticals, qualification‑application requirements, clinical access criteria, and operational guidelines. President Hao Deming and the accompanying experts provided detailed responses and professional guidance, offering a series of constructive recommendations on expanding clinical applications and enhancing disciplinary capabilities following the introduction of authorized medical products and devices.

　　The meeting affirmed that Nanjing Zijin Hospital will take this research visit as an opportunity to comprehensively advance the selection process for its designation as a pilot hospital for innovative international medical devices and pharmaceuticals in Lingshui. Each department will further refine its clinical diagnostic and treatment needs, actively engage in the selection and evaluation of cutting-edge international medical products, and expedite efficient coordination with the association and various stakeholders, striving to bring the first batch of authorized medical devices and pharmaceuticals into clinical use at the earliest possible date. Meanwhile, the hospital will concurrently deepen its efforts to integrate commercial health insurance, leveraging the association’s platform and resources to refine a diversified healthcare payment system, thereby continuously enhancing its service capabilities and overall competitiveness.

　　The successful convening of this research symposium has charted a clear course and roadmap for Nanjing Zijin Hospital’s participation in the development of non‑public medical consortia. Taking this as a strategic lever, the hospital will drive advances in medical technology, strengthen discipline development, and elevate service quality to new heights, thereby contributing the “Zijin Spirit” to meeting the people’s multi‑tiered and diversified healthcare needs.